Loading clinical trials...
Loading clinical trials...
Penfluridol for Relapsed/Refractory Small Cell Lung Carcinoma and Small Cell Cervical Cancer: An Open-Label, Multicenter, Single-Arm Ib/II Trial
Conditions
Interventions
Penfluridol Monotherapy for Relapsed/Refractory Small-Cell Lung or Cervical Cancer
Locations
1
China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Start Date
October 1, 2025
Primary Completion Date
October 1, 2027
Completion Date
October 1, 2028
Last Updated
October 3, 2025
NCT06498635
NCT07144280
NCT05969860
NCT07288034
NCT06660407
NCT06500455
Lead Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions